291 related articles for article (PubMed ID: 30202034)
1. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
Collord G; Tarpey P; Kurbatova N; Martincorena I; Moran S; Castro M; Nagy T; Bignell G; Maura F; Young MD; Berna J; Tubio JMC; McMurran CE; Young AMH; Sanders M; Noorani I; Price SJ; Watts C; Leipnitz E; Kirsch M; Schackert G; Pearson D; Devadass A; Ram Z; Collins VP; Allinson K; Jenkinson MD; Zakaria R; Syed K; Hanemann CO; Dunn J; McDermott MW; Kirollos RW; Vassiliou GS; Esteller M; Behjati S; Brazma A; Santarius T; McDermott U
Sci Rep; 2018 Sep; 8(1):13537. PubMed ID: 30202034
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
3. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
[TBL] [Abstract][Full Text] [Related]
5. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
7. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
8. The correlation of clinical and chromosomal alterations of benign meningiomas and their recurrences.
Och W; Szmuda T; Kulbacki K; Witek K; Sikorska B; Zakrzewska M; Springer J; Reszeć J; Parda A; Liberski PP
Neurol Neurochir Pol; 2016; 50(6):395-402. PubMed ID: 27480481
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
[TBL] [Abstract][Full Text] [Related]
10. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Nassiri F; Mamatjan Y; Suppiah S; Badhiwala JH; Mansouri S; Karimi S; Saarela O; Poisson L; Gepfner-Tuma I; Schittenhelm J; Ng HK; Noushmehr H; Harter P; Baumgarten P; Weller M; Preusser M; Herold-Mende C; Tatagiba M; Tabatabai G; Sahm F; von Deimling A; ; Zadeh G; Aldape KD
Neuro Oncol; 2019 Jul; 21(7):901-910. PubMed ID: 31158293
[TBL] [Abstract][Full Text] [Related]
12. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
15. [MOLECULAR PATHOLOGY OF MENINGIOMAS].
Murnyák B; Csonka T; Hortobágyi T
Ideggyogy Sz; 2015 Sep; 68(9-10):292-300. PubMed ID: 26665490
[TBL] [Abstract][Full Text] [Related]
16. A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.
Chen WC; Vasudevan HN; Choudhury A; Pekmezci M; Lucas CG; Phillips J; Magill ST; Susko MS; Braunstein SE; Oberheim Bush NA; Boreta L; Nakamura JL; Villanueva-Meyer JE; Sneed PK; Perry A; McDermott MW; Solomon DA; Theodosopoulos PV; Raleigh DR
Neurosurgery; 2020 Dec; 88(1):202-210. PubMed ID: 32860417
[TBL] [Abstract][Full Text] [Related]
17. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.
Bollag RJ; Vender JR; Sharma S
Neuropathology; 2010 Jun; 30(3):279-87. PubMed ID: 19780983
[TBL] [Abstract][Full Text] [Related]
19. The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas.
Jiang J; Lin C; Liu N; Zhang Z; Sun Y; Fang X; Qi J
APMIS; 2013 Oct; 121(10):997-1003. PubMed ID: 23879478
[TBL] [Abstract][Full Text] [Related]
20. Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.
Olar A; Wani KM; Wilson CD; Zadeh G; DeMonte F; Jones DT; Pfister SM; Sulman EP; Aldape KD
Acta Neuropathol; 2017 Mar; 133(3):431-444. PubMed ID: 28130639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
